INTRODUCTION
============

Constipation is a common clinical occurrence in children and adolescents, with over 90% of cases that classify as functional gastrointestinal disorders.[@B1] ^,^ [@B2] The prevalence of constipation varies depending on the diagnostic criteria used, and it is considered to be a public health problem.[@B3] The Rome criteria are currently adopted to standardize the diagnosis of constipation in the pediatric population.[@B4] ^,^ [@B5]

An important role of retention behavior has been evidenced in the pathophysiology of functional constipation, due to unpleasant experiences with bowel movements. Recommended treatment includes a combination of dietary interventions (adequate fiber and fluid intake), education, demystification and, where appropriate, toilet training and completion of a bowel movement diary. In the presence of fecaloma, fecal disimpaction and the use of oral laxatives for prolonged treatment are indicated. The effectiveness and safety of these procedures are well established.[@B1] ^,^ [@B5] ^,^ [@B6]

However, for a small portion of patients, conventional treatment does not provide satisfactory improvement, which leads to interest in other therapeutic strategies. There is also a great deal of concern from family members about the prolonged use of laxatives.[@B1] ^.^ [@B7]

It is suggested that prolonged fecal stasis in the colon of patients with constipation has an impact on gut microbiota, which may influence various intestinal functions, including motility.[@B8] ^,^ [@B9] In adults with constipation, the fecal microbiota was found to be different from healthy controls, however the results are heterogeneous.[@B10] ^,^ [@B11] ^,^ [@B12] A study conducted in Ireland in 2005 showed a decrease in the abundance of *Bifidobacterium* and *Lactobacillus*.[@B10] In 2015, a clinical trial conducted in Korea also found a decrease of *Bifidobacterium* spp., and reported a decrease in abundance of the *Bacteroides* species, when compared to the control group.[@B11]

In contrast, in 2016, it was observed in the colonic and fecal mucosa of women with intestinal constipation, that the fecal microbiota profile was not associated with increased colonic transit time, when confounding factors such as age, body mass index and diet were considered. On the other hand, *Faecalibacterium*, *Lactococcus* and *Roseburi*, which are genus of the phylum *Firmicutes,* correlated with decreased colonic transit.[@B12]

The abnormalities observed in the gut microbiota in patients with constipation have increased the use of probiotics for additional support in their treatment.[@B11] ^.^ [@B13] In addition, they are probably more accepted by families than traditionally used laxatives. As such, this systematic review of literature data on gut microbiota and the efficacy of using probiotics for the treatment of constipation in children and adolescents was performed.

METHOD
======

This review article was conducted according to the PRISMA criteria for systematic reviews and meta-analyzes.[@B14] The PubMed, the Scientific Electronic Library Online (SciELO), and the Latin American and Caribbean Health Sciences Literature (LILACS) databases were used to search the literature. A study was conducted on articles in English, Portuguese and Spanish that analyzed the microbiota profile and the use of probiotics in the treatment of constipation in children and adolescents. In PubMed, the period from January 1966 to December 31, 2017 was evaluated. To this end, a broad search was performed using the following terms and operators: (gastrointestinal microbiome OR microbiome OR microbiota OR ecosystem) OR (probiotic OR *bifidobacterium* OR *lactobacillus*) AND constipation. In the LILACS and SciELO databases, no research period was defined. The oldest record in each one up until the last one from December 2017 was considered. The following terms and limits were used: (gastrointestinal microbiome OR microbioma gastrointestinal OR microbiom\$ OR microbiota OR ecosystem OR ­*ecossistema* OR *ecosistema*) OR (probiotic\$ OR bifidobacterium OR lactobacillus) AND (constipation OR *constipação* OR *estreñimiento*). References to articles and other relevant systematic reviews were also consulted.

After reading the titles and abstracts, we selected all original articles that included children and adolescents. To evaluate fecal microbiota in constipation, the articles that compared children and adolescents with constipation and a control group were considered. Inclusion criteria for articles evaluating the use of probiotics in the treatment of constipation were: evaluating children or adolescents aged ≤19 years; including an intervention with any type of probiotic, regardless of the strain, dose and presentation. Research was not restricted to the exclusive evaluation of randomized controlled trials. This systematic review did not include review articles, editorials or commentaries.

RESULTS
=======

At the beginning of the research on microbiota, probiotics and constipation, 559 articles were found, of which 47 were selected for reading. Of these, 12 articles that studied children and adolescents were included in this review.[@B8] ^,^ [@B9] ^,^ [@B13] ^,^ [@B15] ^,^ [@B16] ^,^ [@B17] ^,^ [@B18] ^,^ [@B19] ^,^ [@B20] ^,^ [@B21] ^,^ [@B22] ^,^ [@B23] According to their content, the articles were divided into two categories: evaluation of the relationship between fecal microbiota and constipation; and the use of probiotics in the treatment of functional constipation. [Figure 1](#f1){ref-type="fig"} shows the study's flowchart.

Figure 1Study flowchart.

Thus, four articles evaluated changes in fecal microbiota in constipation in children and adolescents.[@B8] ^,^ [@B9] ^,^ [@B13] ^,^ [@B15] These studies were performed in Italy,[@B8] the United States,[@B9] Holland[@B13] and Brazil,[@B15] and included between 22 and 137 individuals. The methods used to analyze the fecal microbiota were different in each study. The summary of the information in these articles is presented in [Table 1](#t1){ref-type="table"}.

Table 1Characteristics of studies evaluating the gut microbiota of children and adolescents with constipation.Authors, year, reference, locationn (age)division of groupsDefinition of constipationAnalysis of fecal microbiotaResults of children with constipation compared to controlsZoppi et al., 1998[@B8]Italy42 (5-14 years old)28 with constipation14 healthy controlsBowel movement frequency: \<1 every 48 hours and hard stoolsMaterial analyzed:a stool sample.Culture in selective and non-selective media supplemented by biochemical assay- Similar anaerobic total count in individuals with and without constipation. In those with constipation, we observed:- a higher number of anaerobes of the genera *Clostridia* (p \<0.001) and *Bifidobacteria* (p \<0.02);- a greater number of *Clostridium* than *Bacterioides*;- a greater number of *Clostridium* than *Escherichia coli*. In the control group, the counts of *Clostridia*, *Bacteroides* and *E. coli* were similar.Zhu et al., 2014 [@B9]United States22 (10-13 years old)eight obese patients with constipation14 obese controls without constipationNASPGHAN Guideline (2006):[@B39] delay or difficulty having a bowel movement for more than two weeksMaterial analyzed: a stool sample. Pyrosequencing of the 16S rRNA geneIn those with constipation, we observed:- a decrease in the filament *Bacteroidetes*, especially genus *Prevotella* (0.010);- an increase in *Firmicutes*, especially *Lachnospiraceae* (p = 0.042) and *Ruminococcaceae* (p = 0.024);Constipation was not associated with a decrease in *Lactobacillus* and *Bifidobacteria*.Meij et al., 2016 [@B13]Holland137 (4-18 years old)76 with constipation61 healthy controlsRome III Criterion (2006) for functional constipationMaterial analyzed:a stool sample.Microbiota profile based on IS-pro multiplex PCR method- No differences were found in phyla and bacterial diversity according to Shannon's index.In those with constipation, the following were found:- an increase in *Bacteroides fragilis*, *Bacteroides ovatus*, *Bifidobacterium longum*, *Proteus mirabilis*, a species of *Parabacteroides*;- a decrease in *Alistipes finegoldii* and*Ruminococcus* species.Moraes et al., 2016 [@B15]Brazil79 (3-36 months)39 with constipation40 healthy controlsRome III Criterion (2006) for functional constipationMaterial analyzed: a stool sample.Total Bacterial Count, *Lactobacillus* and *Bifidobacterium* by real time PCR- No difference was observed in the counts for total bacterial and bifidobacterium.- In those with constipation, a lower (p = 0.022) concentration of *Lactobacillus* per milligram of stool was observed.[^2]

Zoppi et al.[@B8], using conventional culture techniques, compared 28 children that had constipation with 14 controls, and observed a statistically significant increase in the *Clostridium* and *Bifidobacterium* genres.

In the study performed by Zhu et al.,[@B9] using 16S rRNA gene pyrosequencing, the fecal microbiota of eight children with constipation and obesity were compared with 14 obese controls. The authors observed that the abundance of *Bacteroidetes* is lower in constipation (mainly species of the *Prevotella* genus), while several families and genus of the *Firmicutes* phylum were in greater abundance.

Meij et al.[@B13] used a technique called IS-pro for multiplex PCR (polymerase chain reaction), and observed a greater abundance of bifidobacteria (*Bifidobacterium longum*, *B. fragilis* and *B. ­ovatus*) in individuals with constipation. Fecal microbiota analysis could differentiate between the 76 patients with constipation and the 61 healthy controls with 82% accuracy.

In the study performed by Moraes et al.,[@B15] using real-time PCR to search for *Lactobacillus* and *Bifidobacterium*, a lower concentration of *Lactobacillus* was found per milligram of feces in children with constipation.

The use of probiotics in the treatment of functional constipation has been evaluated in eight articles,[@B16] ^,^ [@B17] ^,^ [@B18] ^,^ [@B19] ^,^ [@B20] ^,^ [@B21] ^,^ [@B22] ^,^ [@B23] which were performed in Italy,[@B16] ^,^ [@B17] Poland,[@B18] ^,^ [@B19] Holland and Poland,[@B20] Taiwan,[@B21] Brazil[@B22] and Iran.[@B23] The main features of the studies are shown in [Table 2](#t2){ref-type="table"}.

Table 2Characteristics of placebo-controlled randomized trials of probiotics / comparison in constipation in children and adolescents.Study, year, referencePatientsProbioticComparison (n)/presentationDurationAllocation concealment/blind analysis/intention to treat/follow-up lossesn (age)Definition of constipationGenus, species and strain (n)Dose/presentationBanaszkiewicz et al., 2005[@B18](2-16 years old)Less than three bowel movements/wk. for at least 12 weeks*L. rhamnosus GG* ATCC 531032 + Lactulose (n=43)2x/day 10 ^9^ CFU/capsulesplacebo + lactulose (n = 41)/capsules26 weeks (12 weeks of treatment)yes/yes/yes/yesBu et al., 2007[@B21]45(1-4 years old)Less than three bowel movements/wk. for more than two months and anal fissure with bleeding or faecal leak or hard/large stools*L. casei rhamnosus* Lcr35 (n = 18)2x/day 8 × 10^8^ CFU/capsulesMgO (n = 18) Placebo (n = 9)/capsules4 weeksyes/yes/yes/yesCoccorullo et al., 2010[@B16]44(5-10 months old)Rome III Criterion (2006) for functional constipation*Lactobacillus* *reuteri* DSM 17938 (n = 22)1x/day 10^8^ CFU/oily suspension in dropsPlacebo (n = 22)/oily suspension in dropseight weeksyes/yes/yes/yesTabbers et al., 2011[@B20]148(3-16 years old)Rome III Criterion (2006) for functional constipation*Bifidobacterium lactis* DN-173 010 (n=74)2x/day 4.25 x 10^9^ CFU/fermented milkPlacebo (n=74)/Low lactose non-fermented dairyfive weeks (three weeks of treatment)yes/yes/yes/yesGuerra et al., 2011[@B22]59(5-15 years old)Rome III Criterion (2006) for functional constipation*Bifidobacterium longum* (n = 29)1x/day 10^9^ CFU/goat yogurtPlacebo (n = 30)/goat yogurtten weeks (crossover after five weeks)yes/yes/yes/yesSadeghzadeh et al., 2014[@B23]48(4-12 years old)Rome III Criterion (2006) for functional constipationProtexin^\*^ (n = 24)1x/day 10^9^ CFU + lactulose/sachetplacebo + lactulose (n = 24)/sachetfour weeksyes/yes/yes/yesRusso et al., 2017[@B17]55(4-12 years old)Rome III Criterion (2006) for functional constipationProbiotic Mix^\*\*^ + PEG 4000 (n = 27)1 sachet/dayPEG 4000 (n = 28)/sacheteight weeksyes/no/yes/yesWojtyniak et al., 2017[@B19]81(1-4 years old)Rome III Criterion (2006) for functional constipation*Lactobacillus casei rhamnosus* Lcr35 (n=46)2x/day 8 × 10 8 CFU/capsulesPlacebo (n = 48)/capsulesfour weeksyes/yes/yes/yes[^3]

The probiotic strains used for the intervention were predominantly from the genera *Bifidobacterium* and *Lactobacillus*: *B. lactis* DN-173010,[@B20] *B. longum*,[@B22] *L. reuteri* DSM 17938,[@B16] *L. casei rhamnosus* Lcr35,[@B19] ^,^ [@B21] *LGG* ATCC 531032,[@B18] *B. breve* M-16 V^®^, *infantis* M-63^®^, e *longum* BB536^®^ [@B17] and Protexin^®^ (*L. casei* PXN 37, *L. rhamnosus* PXN 54, *S. thermophiles* PXN 66, *B. breve* PXN 25, *L. acidophilus* PXN 35, *B. infantis* PXN 27, e *L. bulgaricus* PXN 39).[@B23]

Of these articles, only one found a higher frequency of probiotic therapeutic success in the treatment of constipation with statistical significance, using the strain *Lactobacillus casei rhamnosus* Lcr35.[@B21] Higher bowel movement frequency,[@B16] ^,^ [@B21] ^,^ [@B23] improved stool consistency,[@B21] ^,^ [@B23] reduced abdominal pain,[@B21] reduced pain during bowel movements [@B22] and flatulence reduction were observed.[@B20] The main results are shown in [Table 3](#t3){ref-type="table"}.

Table 3Results summary of studies evaluating the role of probiotics in the treatment of constipation in children and adolescents.Author, year, reference and placeProbioticResults of children with constipation compared to control groupBanaszkiewicz et al., 2005[@B18]Poland*L. rhamnosus GG* (ATCC 531032)Treatment success^a^ was similar (p\> 0.05) at the 12^th^ week (experimental group=72% and control group=68%) and at the 24^th^ week (experimental group =64% and control group=65%).There was no difference between the groups regarding weekly number of bowel movements, the force of the bowel movement, fecal escape and the number of required doses of laxatives.Bu et al., 2007[@B21]Taiwan*L. casei rhamnosus* Lcr35Greater (p=0.01) treatment success^a^ in the magnesium oxide (72.2%) and probiotic (77.8%) groups compared to the placebo (11.1%).The magnesium oxide and probiotic groups presented a higher (p = 0.03) frequency of bowel movement, a lower (p = 0.01) frequency of hardened stools and a lower (p = 0.04) frequency of glycerin enema use in comparison to the placebo.Episodes of abdominal pain were less frequent (p = 0.03) in the probiotic group compared to the magnesium oxide and placebo groups.There was an increase in the percentage of lactobacilli in anaerobic microbiota after probiotic treatment (p = 0.03) and when compared to the magnesium oxide and placebo groups (p = 0.02), there was no correlation with bowel movement frequency.There was no difference between the groups regarding the frequency of lactulose use, bowel movement episodes and appetite alteration.Coccorullo et al., 2010[@B16]Italy*Lactobacillus* *reuteri* DSM 17938No definition of therapeutic success.Higher frequency of probiotic bowel movements in the second (p = 0.042), fourth (p = 0.008) and eighth (p = 0.027) weeks of treatment versus the control.There was no difference between groups with regard to stool consistency.There was an increase (p = 0.02) of inconsolable crying episodes in the probiotic group. In the control group, an increase in inconsolable crying was also observed, however, it did not reach statistical significance (p = 0.08).Tabbers et al., 2011[@B20]Holland and Poland*Bifidobacterium lactis* DN-173 010 (n=74)Treatment success^b^ was higher in the probiotic group (38%) compared to the placebo group (24%), but there was no significant difference (p=0.06).In the probiotic group, a reduction (p = 0.02) in flatulence frequency was observed.There was no difference between the probiotic and control groups regarding bowel movement frequency, stool consistency, fecal incontinence, pain during bowel movements, abdominal pain and bisacodil use.Higher bisacodil intake was observed in the control group (p=0.0069).Guerra et al.,2011[@B22]Brazil*Bifidobacterium longum* (n = 29)They do not present total data obtained in the two intervention periods with probiotic or control. They mention that in the probiotic group, considering all the results, there was a significant difference in the frequency of bowel movements, pain in bowel movements and abdominal pain.Sadeghzadeh et al., 2014[@B23]IranProtexin^®^No definition of therapeutic success.At the end of the fourth week it was found that the probiotic group had a higher (p = 0.042) bowel movement frequency and an improvement (p = 0.049) in stool consistency when compared to the placebo group.In the first week of intervention, a lower (p=0.030) frequency of fecal incontinence, a lower frequency (p=0.017) of abdominal pain and a greater weight gain (p=0.002) was found. These variables were similar in the fourth week of the study.Russo et al., 2017[@B17]ItalyBrief bifidobacterium M-16 V^®^ , Infant Bifidobacterium M-63^®^ and Bifidobacterium longum BB536^®^.*Bifidobacterium* l*ongum* BB536^®^In the second week of the study, treatment success^c^ was higher with PEG (72%) compared to the PEG + probiotic mixture group (59%) (p=0.02).After one month (the fourth week), there was no difference in treatment success between the PEG group (88%) and the PEG + probiotic mixture group (81.8%).There was no difference between groups regarding bowel movement frequency, stool consistency, abdominal pain, fecal incontinence and rectal bleeding after two months (eighth week) of study.One month after the end of the study (12^nd^ week), a clinical remission rate was observed in the PEG + probiotic mixture group in 64% of patients and 52% in the PEG-only group (p=0.28).Wojtyniak et al., 2017[@B19]Poland*Lactobacillus casei rhamnosus*Lcr35There was no difference in treatment success^a^ between the groups.In the probiotic group, there was a lower (p = 0.005) bowel movement frequency in allof the studied weeks compared to the placebo group.Comparing from the baseline to the fourth week of study, there was an increase (p\<0.001) in bowel movement frequency and an improvement (p\<0.001) in stool consistency in both groups.[^4]

DISCUSSION
==========

Microbiota of children with constipation
----------------------------------------

Despite the rapid growth of knowledge and scientific literature on gut microbiota and probiotics, the present systematic review has shown that information is very limited regarding the profile of gut microbiota in children and adolescents with constipation. No systematic review on this topic was found.

As can be seen from [Table 1](#t1){ref-type="table"}, the four articles that evaluated gut microbiota in children with constipation used different analysis methods. Thus, it is difficult to compare the differences found in the gut microbiota in each of the studies.[@B24]

It is evident that the results obtained on the fecal microbiota of children and adolescents with constipation are discrepant. The different methodologies used for the fecal microbiota analysis of the studied individuals and the different species of bacteria evaluated made it impossible to determine a specific pattern of fecal microbiota abnormalities in patients with constipation.

Regarding the study conducted in the United States,[@B9] it should be noted that patients that did and did not have constipation were evaluated, however, all were obese. It should be noted that obesity alone is associated with changes in gut microbiota.[@B13] ^,^ [@B25] ^,^ [@B26]

Other aspects that hinder the comparability of the obtained results are the high inter-individual variability of the fecal microbiota and the clinical heterogeneity of the studied populations.[@B13] ^,^ [@B27] Another factor is the age of the patients studied, considering that children under the age of three are in the microbiota implantation phase, which could interfere with the results.[@B28]

Therefore, further studies with larger and more homogeneous series, preferably using modern molecular biology techniques, are needed to establish the gut microbiota profile of children and adolescents with constipation, more accurately.

The use of probiotics for the treatment of constipation in children and adolescents
-----------------------------------------------------------------------------------

According to the literature, there are several mechanisms that can potentially explain the action of probiotics in the treatment of functional constipation: modification of the gut microbiota, considering the changes that have been shown in individuals with constipation; increased production of lactate and short chain fatty acids, reducing luminal pH, which could improve colonic peristalsis and decrease intestinal transit time.[@B8] ^,^ [@B29] ^,^ [@B30] ^,^ [@B31] Taking this into consideration, there is a growing interest in using probiotics in the treatment of constipation.

The definition of therapeutic success is an important criterion when evaluating the effectiveness of therapeutic interventions. In children and adolescents with constipation, it is important to evaluate not only bowel movement frequency but also stool consistency as parameters for therapeutic success.[@B32] As described in [Table 3](#t3){ref-type="table"}, among the clinical trials included in this systematic review, only one included stool consistency as part of the definition of therapeutic success.[@B17] In some of the articles, therapeutic success was not defined and different variables were evaluated separately.[@B16] ^,^ [@B22] ^,^ [@B23]

As can be seen from [Table 2](#t2){ref-type="table"}, three studies performed interventions with a laxative-associated probiotic: polyethylene glycol[@B17] and lactulose.[@B18] ^,^ [@B23] However, these medications are, by themselves, effective therapeutic interventions for the treatment of constipation[@B1] ^,^ [@B4] ^,^ [@B5] and their association with probiotics can be important to note, because the therapeutic role of probiotics may be covered up. Furthermore, it was difficult to compare studies in relation to the duration of constipation and the use of laxatives, which may interfere with the success of treatment with probiotics. Thus, in future studies, this type of design should be avoided.

Among the clinical trials in which probiotics without laxatives were used, only one study found greater therapeutic success from the probiotic when compared with the placebo.[@B21] In this article, it was further observed that the effect of the probiotic *L. casei rhamnosus* Lcr35 was similar to that of magnesium oxide administered in a third group of the clinical trial ([Table 3](#t3){ref-type="table"}).

In [Table 3](#t3){ref-type="table"}, we can also see that irregular beneficial effects of certain probiotics were found in some clinical manifestations of constipation, which resulted in increased bowel movement frequency, [@B16] ^,^ [@B21] ^,^ [@B23] improved stool consistency,[@B21] ^,^ [@B22] ^,^ [@B23] reduced abdominal pain,[@B21] reduced pain from bowel movements [@B22] and reduced flatulence. [@B20]

In these intervention studies using probiotics, the composition of the intestinal microbiota before and after probiotic administration was not evaluated. Thus, the observed clinical effects on motility and characteristics of intestinal habit attributed to the use of probiotics could not be associated with specific changes in the composition of the gut microbiota.

Regarding the methodological quality of the analyzed clinical trials, it is worth noting that the only randomized crossover clinical trial [@B22] did not mention a period of ­*wash-out* between the intersection of the interventions. Thus, in the second stage of the study, there could have been residual effects of the probiotics. It is also important to report that several studies did not have an adequate sample size, as they were composed of convenience samples with a small number of participants, which makes comparison and the reliability of the data obtained, difficult.

Thus, it was found that the intervention studies with probiotics included in this systematic review are heterogeneous with regard to the population studied, the probiotic strains used, the dosages used for treatment, the duration of the study, the follow-up, the definitions, and the parameters used to evaluate the effect of intervention on the control of constipation in children and adolescents. Therefore, the data obtained do not allow for specific recommendations to be made regarding the use of probiotics in the treatment of functional constipation.

In the literature, five systematic review articles were found,[@B30] ^,^ [@B33] ^,^ [@B34] ^,^ [@B35] ^,^ [@B36] Two had a meta-analysis, [@B30] ^,^ [@B34] which addressed the use of probiotics in the treatment of functional constipation in children and adolescents. An article published in 2010[@B33] included two clinical trials in children[@B18] ^,^ [@B21] and three adult trials, and concluded that only *L. rhamnosus* Lcr35 showed a beneficial effect for the treatment of constipation in children. A systematic review and meta-analysis published in 2014[@B34] evaluated the use of probiotics for pediatric functional gastrointestinal disorders. Probiotics *LGG*, *L. reuteri* DSM 17 938 and VSL \# 3^®^ have been reported to have a better effect than placebo in the treatment of functional abdominal pain and irritable bowel syndrome. However, no evidence was found indicating the efficacy of probiotics in the treatment of functional constipation. A systematic review published in 2016 [@B35] on the use of prebiotics, probiotics and symbiotics for the treatment of functional constipation in children concluded that there is still insufficient evidence to support the recommendation of probiotics in this treatment. At the same time as the present article was being completed, two systematic reviews were published[@B30] ^,^ [@B36] addressing this theme. In 2017, a systematic meta-analysis review highlighted the effectiveness of probiotics for improving bowel movement frequency in Asian children, and highlighted the heterogeneity of the studies.[@B30] Another systematic review, published that same year, included studies published up until February 2017, and evaluated seven clinical trials.[@B16] ^,^ [@B18] ^,^ [@B19] ^,^ [@B20] ^,^ [@B21] ^,^ [@B22] ^,^ [@B23] It was noted that some probiotic strains had some effects on the frequency of bowel movements, but no effects on the frequency of fecal incontinence and abdominal pain.[@B36]

Given the heterogeneity of clinical trials conducted with children and adolescents, there is a need to standardize the criteria and definitions used to compare the effects of different therapeutic interventions, as mentioned in the literature.[@B37] ^,^ [@B38] Therefore, regardless of the analyzes performed, there is not enough evidence to support the recommendation of probiotics for the treatment of constipation in children and adolescents. The ideal approach and treatment of fecal disimpaction is the use of oral medication and the education of family members and patients[@B39].

It was not possible to determine a specific pattern of fecal microbiota abnormalities of constipation in children and adolescents.

Irregular beneficial effects of probiotics were evidenced in some clinical manifestations of constipation in this population. However, clinical trials are still scarce and heterogeneous, and their results are controversial.

To date, there is no scientific evidence to support probiotic supplementation for the treatment of functional constipation in children and adolescents.

Thus, further research with well-established and homogeneous methodologies is needed to determine causal relationships between fecal microbiota alteration and constipation, as well as on the effectiveness of using probiotics to treat children and adolescents
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